Director Stephen Sabba has sold 1,893 shares of Ligand Pharmaceuticals Inc (LGND, Financial) on March 5, 2024, according to a recent SEC filing. The transaction was executed at an average price of $74.3 per share, resulting in a total value of $140,615.9.
Ligand Pharmaceuticals Inc is a biopharmaceutical company focused on developing or acquiring technologies that help pharmaceutical companies discover and develop medicines. The company's business model is based on revenue from partnerships and collaborations with pharmaceutical and biotechnology companies, as well as from royalties, licensing fees, and milestone payments.
Over the past year, Stephen Sabba has sold a total of 8,301 shares of Ligand Pharmaceuticals Inc and has not made any purchases of the stock. The insider transaction history for the company shows a pattern of more insider sales than buys over the past year, with 1 insider buy and 6 insider sells recorded.
The market cap of Ligand Pharmaceuticals Inc stands at $1.285 billion as of the date of the insider's recent sale. The stock's price-earnings ratio is 25.43, which is lower than the industry median of 28.24 and also below the company's historical median price-earnings ratio.
According to the GuruFocus Value, Ligand Pharmaceuticals Inc has a price-to-GF-Value ratio of 1.57, with the stock's price at $74.3 and the GF Value at $47.34. This indicates that the stock is Significantly Overvalued based on its GF Value.
The GF Value is determined by considering historical trading multiples such as price-earnings ratio, price-sales ratio, price-book ratio, and price-to-free cash flow, along with a GuruFocus adjustment factor based on the company's past returns and growth, and future business performance estimates from Morningstar analysts.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
